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Abstract
The health authorities have recently accepted the routine provision of highly active antiretroviral
therapy to persons living with AIDS in South Africa. There is a need to investigate the impact of
HAARTon the health-related quality of life of people living with HIV/AIDS (PLWHA) in a resource-
poor environment, as this will have an influence on compliance and treatment outcome. The aim of
this study was to explore whether HAART is efficacious in improving the self-reported health-related
quality of life (HRQoL) in a group of PWLA in WHO Stages 3 and 4 living in a resource-poor
community. A quasi-experimental, prospective repeated measures design was used to monitor the
HRQoL over time in participants recruited to an existing HAART programme. The HRQoL of 117
participants was determined through the use of the Xhosa version of the EQ-5D and measurements
were taken at baseline, one, six and 12 months. At the time of the 12-month questionnaire, 95
participants had been on HAART for 12 months. Not all participants attended all follow-up visits, but
only two participants had withdrawn from the HAART programme, after two or three months.
At baseline, the rank order of problems reported in all domains of the EQ-5D was significantly
greater than at 12 months. The mean score on the global rating of health status increased significantly
(p B /0.001) from a mean of 61.7 (SD /22.7) at baseline to 76.1 at 12 months (SD /18.5) It is
concluded that, even in a resource-poor environment, HRQoL can be greatly improved by HAART,
and that the possible side effects of the drugs seem to have a negligible impact on the wellbeing of the
subjects. This bodes well for the anticipated roll-out of HAART within the public health sector in
South Africa.
Introduction
The HIV/AIDS pandemic has reached catastrophic proportions in sub-Saharan Africa. In
2002, the incidence rate in South Africa was estimated to be 2% and the prevalence rate for
the total population to be 14.2% (Dorrington et al., 2002). Projections indicate that, in the
absence of antiretroviral treatment, the number of deaths due to AIDS is expected to result
in a cumulative total of five to seven million in South Africa by 2010 (Dorrington et al.,
2001). A recent survey has indicated that the prevalence of HIV in South Africa is highest in
young adults, particularly those living in informal or township settings (Shishana &
Simbayi, 2002). In 2002, it was estimated that of those infected in South Africa, 18% were
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in the third stage of the disease and 7% were in the final stage of the disease (Dorrington
et al., 2002).
In 2002, Cullinan reported that the South African government had taken tentative steps
to provide antiretroviral therapy (Cullinan, 2002) and by March 2004, it was in the process
of expanding access to HAART within the public sector. However, there was still some
concern that the treatment was ‘toxic’, a legitimate concern, both for the individual who
might experience unpleasant side effects and for the community if this leads to non-
compliance and drug resistance. One way to detect undesirable side effects of HAART is to
monitor the health-related quality of life (HRQoL; Han et al., 2002) of PLWHA who are on
treatment. It would be reasonable to expect that, if the toxic effects are significant, PLWHA
would experience either maintenance of or a decline in baseline HRQoL and that their
HRQoL would remain worse than others living in the same community. In addition,
improvements in functional status and wellbeing can be regarded as essential outcomes of
the management of chronic diseases (Murri et al., 2003) and as such should be measured
regularly.
Health-related quality of life is a multidimensional concept that includes global health
perspectives, symptom status, functional status, biological and physical variables, individual
and environmental characteristics and general health perceptions (Wilson & Cleary, 1995).
There are many different instruments that have been developed to describe and quantify
HRQoL. These include HIV-specific instruments such as the Medical Outcomes Study-
HIV (Smith et al., 1996), the HIV Overview of Problems-Evaluation System (O’Leary
et al., 1998) and the WHOQOL module for international assessment in HIV/AIDS
(WHOQOL Group, 2003). The EQ-5D, a generic HRQoL instrument that describes
health state in terms of five dimensions (mobility, self-care, usual activities, anxiety/
depression and pain/discomfort) (Brooks & EuroQol Group, 1996) has been also used to
examine HRQoL in participants with HIV (Badia et al., 1999; Delate & Coons, 1999).
Some instruments have specifically been tested in an African context. The SF36 was used
to monitor HRQoL in PLWHA in South Africa (O’Keefe & Wood, 1996) and the EQ-5D
has been validated in both Zimbabwe (Jelsma et al., 2001) and South Africa (Jelsma et al.,
2004). Mast et al. (2004) report that patient-reported measures of HRQoL are likely to be
reliable and valid methods of assessing the impact of different HIV/AIDS interventions
within an African context.
In 2001, the international humanitarian aid organization, Me ´decins Sans Frontie `res, in
partnership with the Western Cape Provincial Department of Public Health, began to
provide care and treatment to PLWHA in a resource-poor township outside of Cape Town
which has a population of about 500,000, an estimated prevalence of 50,000 living with
HIV and in 2003, an antenatal prevalence rate of 25%. The details of the programme and
the impact on morbidity are described elsewhere (Coetzee et al., 2004). Coetzee et al.
documented the effect of the programme on morbidity and the survival rate after 24 months
of treatment was reported to be 86.4%, even though more than half had CD4 cell counts of
less than 50 at the start of treatment. The intention of the current study was to monitor the
HRQoL of the people who participated in this programme.
Aim
The aim of this study was to explore whether HAARTwas efficacious in improving the self-
reported health-related quality of life (HRQoL) in a group of PWLA in WHO Stages 3 and
4 living in a resource-poor community.
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The specific objectives of the study were to determine if there was a significant difference
in HRQoL between the scores of participants living with HIV/AIDS at baseline, i.e. before
initiation of HAART, and 12 months post-initiation. A secondary objective was to describe
when, if at all, the HRQoL changed over this 12-month period and whether it improved or
deteriorated.
Methods
As the use of a control group would have raised serious ethical concerns, a quasi-
experimental, prospective repeated measures design was used to monitor the HRQoL over
time in new participants recruited to the MSF programme.
Participants
All participants in this study were receiving HAART through one of the three HIV clinics.
The criteria for inclusion on the programme include: (1) clinical criteria (WHO Stages 3 or
4 signifying former or current HIV-related illness, including tuberculosis; CD4 count less
than 200/mm
3), (2) social criteria (resident of the area; willingness to attend monthly
support group;), and (3) adherence criteria (at least three months of attendance at clinic;
prior adherence to TB treatment; selection of a treatment assistant; regularity of clinic
visits). All patients on treatment were residents of the same resource-poor area.
Instrumentation
The Xhosa version of the EQ-5D was used. The major advantage of this instrument is that
there is a Xhosa version recognized by the EuroQol Group, which was produced by
adhering strictly to the official translation protocol (Mkoka et al., 2003). The reliability and
validity of the instrument has been established in the population under consideration in the
current study. For the above reasons, the EQ-5D was regarded as an appropriate outcome
measure for studies with PLWHA whose first language is Xhosa. The health state was
described using the five EQ-5D domains: mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. The measurement of health status was done using the
visual analogue scale, which is incorporated into the EQ-5D, and a utility index calculated
using values attributed to the levels of each domain. The instrument was self-administered,
although the research assistants gave assistance to the participants who were not literate, a
total of nine in all. The administration was standardized through holding a training session
and by the fact that only three field workers did all the data collection.
Procedure
Patient recruitment lasted from April to December 2002 and data collection for analysis
ended in October 2003. The designated multidisciplinary HIV clinics treat patients who are
in the late stages of HIV/AIDS (WHO Stages 3 or 4). The programme was ongoing at the
time of writing. Clients attending the HIV clinics who were determined to be eligible for
HAART by clinical, biological, adherence and social criteria were presented to a
community selection committee. Those approved by the selection committee returned to
the clinic to discuss the implications of HAART with their counsellor and doctor. At this
visit, they received a detailed consent form to participate in the HAART programme. They
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returned to the clinic, generally within two weeks, to sign the consent form and begin
receiving HAART.
At this visit, immediately prior to the initiation of HAART, clients were asked if they
would be willing to participate in the HRQoL study and other studies, including
documentation of compliance (Darder et al., 2003) and the economic impact of HIV/
AIDS (to be published elsewhere). For clients that agreed, informed consent was obtained
and the baseline EQ-5D measure was taken. These clients were followed-up at one, three,
six and 12 months following initiation of HAART. Participants who did not attend the clinic
were followed-up by the interviewers and counsellors to determine the reason for not
attending. Six Xhosa-speaking interviewers attended a training session and took part in a
pilot project to test the feasibility of the studies. Three were subsequently employed solely to
interview clients awaiting their clinical consultation and performed no other functions in the
clinics.
Data analysis
Descriptive statistics were used to describe the health states of the participants at each data
collection point. The data of participants who died during the course of the study were
excluded from analysis as initial inclusion might decrease the mean HRQoL compared to
later analysis when their information would be excluded.
In order to restrict the number of tests, only the difference in the rank ordering of the
domain scores and between the mean VAS scores at baseline and 12 months were tested
using the Wilcoxon sign rank test and paired t-test, respectively. The results at the other
time periods were presented graphically.
Ethical considerations
The University of Cape Town Medical Research Ethics Board gave ethical approval.
Informed consent was given by the participants separately for participation in the HAART
programme and the HRQoL study. HRQoL participation was only requested after clients
had already been approved to begin treatment. It was made clear that participation was
voluntary and did not affect participation in the HAART programme in any way. Individual
results from the study were confidential and not provided to the clinic staff. Interviews were
conducted in a private venue with no one present aside from the client and the interviewer.
Results
No recipient of HAART refused to take part in the HRQoL study. An initial 139
participants were recruited, of these 11 never commenced HAART, one moved to
Johannesburg and ten died during the course of the study (Table I). The remaining 117
Table I. Attendance of participants at each appointment.
Baseline 1 month 3 months 6 months 12 months
Attended 95 102 97 98 83
Data missing for this visit 21 15 21 19 13
Eligible for attendance 117 117 117 117 97
Note: Not all participants attended every follow-up visit. Apart from two participants who were lost to follow-up,
all participants were still receiving medication at the time of analysis.
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constituted the experimental group and, of these, 74.5% were female. Not all of the 117
participants were seen by the research assistants at each visit, due to logistic and
administrative problems. At the time of the 12-month questionnaire, 95 participants had
been on HAART for 12 months, of which 84 were interviewed. However, with the
exception of two participants who had not been interviewed since June, all participants were
still receiving HAART at the time of analysis.
Table II depicts the percentage of respondents reporting problems on the five different
domains and the mean scores of the values of the health states and the Visual Analogue
Scale. The rank order of self-care (p /0.031), usual activities (p B /0.01), pain and
discomfort (pB /0.01) and anxiety/depression (p /0.023) were all significantly different
between baseline and 12 months with more people reporting problems, in the baseline
scores.
Figures 1 and 2 demonstrate the almost linear improvement in health state from baseline
to 12 months, both with regard to the number of participants reporting problems in each
Table II. Scores on the ﬁve descriptor domains, the mean values of the health states (calculated using the
recommended EQ-5D value set) and the Visual Analogue Scale scores at the different time periods.
Reference
Sample Baseline 1 month 3 months 6 months 12 months
n 106 95 102 97 98 83
Mobility
No problems 85.2 73.7 82.4 86.6 83.7 89.2
Some problems 14.8 23.2 16.7 13.4 15.3 10.8
Severe problems 0.0 3.2 1.0 0.0 1.0 0.0
Total 100.0 100.0 100.0 100.0 100.0 100.0
Self-care
No problems 95.3 90.5 91.2 94.8 100.0 100.0
Some problems 4.7 7.4 8.8 5.2 0.0 0.0
Severe problems 0.0 2.1 0.0 0.0 0.0 0.0
Total 100.0 100.0 100.0 100.0 100.0 100.0
Usual activities
No problems 89.8 75.8 79.4 87.6 89.8 94.0
Some problems 9.3 15.8 17.6 11.3 9.2 4.8
Severe problems 0.9 8.4 2.9 1.0 1.0 1.2
Total 100.0 100.0 100.0 100.0 100.0 100.0
Pain/discomfort
No problems 66.7 29.5 45.1 53.6 60.2 73.5
Some problems 25.9 64.2 48.0 44.3 37.8 24.1
Severe problems 7.4 6.3 6.9 2.1 2.0 2.4
Total 100.0 100.0 100.0 100.0 100.0 100.0
Anxiety/depression
No problems 75.9 68.4 83.3 79.4 82.7 85.5
Some problems 21.3 28.4 16.7 19.6 13.3 13.3
Severe problems 2.8 3.2 0.9 1.0 4.1 1.2
Total 100.0 100.0 100.0 100.0 100.0 100.0
Visual Analogue Scale
Mean score 80.1 61.7 70.2 71.4 73.9 76.1
Standard deviation 20.4 22.7 18.9 18.1 19.8 18.5
Note: For comparison, the results of a community survey of randomly selected participants from the same
community (Jelsma et al., 2004) are included.
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domain and the mean values of the health states. The VAS improved from a mean of 61.7
(SD /22.7) at baseline to 76.1 at 12 months (SD /18.5), an improvement of 14.4%.
Although the VAS score showed steady improvement, more than half of the improvement
was already evident after one month (8.55%), as is depicted in Figure 2. The responses of a
randomly selected community sample of 108 subjects who were within the same age range
as the HIV sample are included in both of these figures for comparison. These responses
were gathered in 2003 during a study on the reliability of the Xhosa version of the EQ-5D
(Jelsma et al., 2004). The baseline VAS scores were not significantly correlated with the
final VAS scores (rho /0.15, p /0.23), but the one-, three- and six-month scores correlated
significantly (rho /0.44, 0.70, 0.65, p B /0.01, respectively) with the 12-month VAS score.
Discussion
The participants of the study were all residents of an impoverished suburb of Cape Town.
As in other community-based surveys (Jelsma et al., 2002), there was a preponderance of
women respondents in the reference sample. This was also true of the participants and
could be because approximately 14% of those on the HAART were referred from
participants in the local prevention of maternal-to-child-transmission programme, which
would also contribute to this bias.
The results of the study indicate that not only did the HRQoL of life of PLWHA not
deteriorate during the course of the study, but that it demonstrated progressive
improvement. HAART appeared to improve HRQoL through improving the health
condition and in itself did not seem to result in any deterioration through toxic effects.
This marked improvement in HRQoL compares very well with results from another trial, by
Revicki et al. (1999), who compared triple combination therapy (SQV/ddC/ZDV) to a two-
drug combination therapy (ddC/ZDV). They found that no improvement in either physical
functioning or VAS score was reported, and maintenance of HRQoL was considered a
successful outcome, achieved by the triple therapy but not by the other two-drug
combinations. However, as they reported a higher baseline VAS score of 78 (compared
to the VAS score of 62 in the current study), a ceiling effect would make maintenance of this
score a valid goal of treatment for the participants in their study.
When compared to the domain and VAS responses of a community sample drawn from
the same area (Jelsma et al., 2004), the 12-month VAS remained lower, although the
number of problems reported in the different domains was less (Figures 1 and 2). There
seemed to be a discrepancy detected between the reporting of problems with the different
domains and with the more global VAS score. Despite having an equivalent or better
objective health state in terms of the five descriptor domains than the community sample,
the participants still reported a VAS score mean of five lower than the reference sample.
The more subjective nature of the VAS is also evident in that the participants demonstrated
an immediate and significant increase in VAS in response to HAART, whereas the
improvement in the descriptor domains was most evident at three months. Preliminary
studies indicate that adherence to the HAART regime is high (Darder et al., 2003) and this
may in part be ascribed to the steady improvement in HRQoL seen over the 12 months.
However, the VAS score would indicate that, after an initial rapid improvement, the
participants still perceive their health status to be worse than the reference sample. This is
borne out by the significant correlations between the one-month VAS score and the other
scores, when compared with the baseline score. This might have implications for adherence,
and the other strategies that are in place within the programme (such as continued
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Figure 1. Reported level of problems in each of the ﬁve domains (n at baseline /96, at one month /102, three
months /97, six months /98 and 12 months /83).
For comparison the results of a community survey of randomly selected participants from the same community
(Jelsma et al., 2004) are included.
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counselling and peer support groups)(Darder et al., 2003) will become ever more
important to maintain the present high levels of adherence.
With the routine provision of HAART becoming a reality for PLWHA in South Africa, it
is expected that the life span of a PLWHA will be considerably extended and, as Wu (2000,
p. 1450) suggests, the ‘most important questions will be how to maximize quality of life’.
Continual monitoring of HRQoL will contribute to the evaluation of programmes and the
identification of the most effective regimes of treatment with the least side effects. The EQ-
5D performed well and, as suggested by other authors (Delate & Coons, 2001; Dorman
et al., 1998), appeared to be a robust instrument, capable of discriminating between
participants and reference group and of detecting improvement over time. However, it is
important to note that although the Xhosa version of the EQ-5D has undergone validation
and reliability testing in both community and disabled and hospitalized participants, it has
not been validated for use in people living with HIV/AIDS specifically. For example, the
omission of domains relating to vitality and sleep, which appear to be consistently
compromised in PLWHA (O’Keefe & Wood, 1996; Revicki et al., 1999; Starace et al.,
2002), might mean that these important aspects of HRQoL are not captured. Han et al.
(2002) argue for the use of a brief and effective HRQoL instrument in HIV/AIDS research
and management. The simplicity and ease of administration of the EQ-5D might make up
for this failing, particularly if it is to be used routinely or, as in this study, as part of ongoing
monitoring of services.
A well-designed and managed HAART programme can be very successful within a
resource-constrained environment. Whereas some participants did develop side effects, the
HRQoL of the majority improved progressively over the 12 months of the study. However
these results were obtained with an urban group of mostly female participants and should
only be generalized to the general population, particularly males and rural dwellers, with
caution.
Figure 2. Mean scores and 95% Conﬁdence Intervals of values of the Visual Analogue Scale scores.
Note that some participants did not ﬁll in the VAS. For comparison the results of a community survey of randomly
selected participants from the same community (Jelsma et al., 2004) are included.
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Conclusion
HRQoL is severely compromised in participants at an advanced stage of AIDS. After
initiation of HAART, there is progressive improvement until at 12 months few problems are
reported in any domain. However, the self-reported Visual Analogue Scale score, while
significantly higher than baseline, still remains lower than the scores reported in other
community samples. The toxic effects of the treatment programme would appear to be
minimal, but, as the VAS score remains depressed, there may be a need for continuing
support to ensure adherence after the first year of treatment.
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